ACS Bio & Med Chem Au

ACS Bio & Med Chem Au is a fully open access, peer reviewed journal of the American Chemical Society that publishes experimental, computational and theoretical research on biological and medicinal chemistry, and it has been published since December 2021.《美国化学会生物与药物化学开放获取版》是美国化学会发行的完全开放获取同行评议期刊，刊发生物化学与药物化学领域的实验、计算与理论研究，2021 年 12 月创刊以来一直出版。

Scope

• The publisher's own guidelines describe the journal as a broad scope, fully open access title publishing letters, articles, reviews, perspectives and other article types across all aspects of biological chemistry, medicinal chemistry and related interdisciplinary fields.出版方自己的作者指南把该刊描述为宽口径的完全开放获取刊物，刊发信件、论文与综述，以及观点文章和其他类型的文章，覆盖生物化学、药物化学与相关交叉学科的各个方面。

• It welcomes studies ranging from fundamental discoveries and methodological advances to translational and clinical applications, provided they offer significant new chemical, biological, mechanistic or therapeutic insight.该刊欢迎从基础发现与方法学进展延伸到转化与临床应用的研究，前提是这些研究能带来显著的化学与生物、机理以及治疗学方面的新认识。

• The scope covers experimental, computational and theoretical research that advances understanding of the molecular basis of biological function, disease processes and therapeutic intervention.刊载范围涵盖实验、计算与理论三类研究，只要它们能推进对生物学功能、疾病过程与治疗干预之分子基础的认识。

• The named areas of interest include chemical biology, medicinal chemistry and synthetic biology.官方列出的关注领域包括化学生物学、药物化学与合成生物学。

• Disease biology, cell biology and structural biology appear in the same list.疾病生物学、细胞生物学与结构生物学列在同一份清单里。

• Biophysics, neuroscience and nucleic acid biology are named as well.生物物理、神经科学与核酸生物学同样在列。

• Natural products research and agriculture and food related chemistry complete the list of areas.天然产物研究与农业食品相关的化学构成了这份领域清单的最后两项。

• Within medicinal chemistry the journal welcomes work on the discovery, design, synthesis, optimisation and biological evaluation of bioactive molecules, both small molecules and larger therapeutic modalities.在药物化学方向，该刊欢迎生物活性分子发现与设计方面的研究，也接受合成与优化以及生物学评价方面的稿件，既收小分子也收更大的治疗分子。

• Topics of interest include structure activity relationships, target identification and validation, pharmacology, molecular mechanisms of action, drug delivery and delivery systems, imaging agents, translational science and emerging therapeutic technologies.受关注的具体题目包括构效关系、靶点鉴定与验证和药理学，也包括分子作用机制、药物递送与成像试剂，以及转化科学和新兴治疗技术。

• Computational, cheminformatics, artificial intelligence and structure based design studies are encouraged when they bring substantial biological or chemical insight and, where appropriate, are supported by compelling experimental validation.计算研究与化学信息学、人工智能类研究，以及基于结构的药物设计研究都会受到鼓励，前提是它们带来实质的生物或化学认识，并在必要时配有有力的实验验证。

• The journal also welcomes contributions on infectious diseases, covering pathogens, host pathogen interactions, diagnostics, therapeutics, vaccines, antimicrobial discovery and drug delivery technologies.该刊也欢迎聚焦传染病的稿件，涉及病原体与宿主之间的相互作用，关注点包括诊断与治疗、疫苗，以及抗菌药物发现和药物递送技术。

• Manuscripts should show clear significance to the biological and medicinal chemistry communities and advance fundamental understanding or practical applications in human, animal, plant or environmental health.稿件须对生物化学与药物化学界显示明确意义，并在人类、动物与植物健康以及环境健康方面推进基础认识或实际应用。

• The launch editorial set out the founding remit, which spans experimental and theoretical studies on the chemical, physical, mechanistic or structural basis of biological or cell function across all domains of life.创刊社论给出了创刊时的范围设定，涵盖在生命各个域中关于生物学功能或细胞功能之化学与物理基础、机理基础以及结构基础的实验与理论研究。^[1]

• That remit reaches natural products research, nucleic acid biology and neuroscience, as well as structural biology, biophysics, agriculture and food.这一范围延伸至天然产物研究、核酸生物学与神经科学，也涵盖结构生物学、生物物理以及农业与食品方向。

• Because the remit is broad, the journal accepts submissions that would be in scope for any of the other ACS biological chemistry, chemical biology or medicinal chemistry journals but where a fully open access journal is required.正因范围宽泛，该刊接受那些本可投给美国化学会其他生物化学、化学生物学或药物化学期刊的稿件，只要作者需要完全开放获取刊物。

• The publisher says the journal publishes the chemical, physical, biological, mechanistic and structural basis of biological function.出版方称该刊报道的是生物学功能的化学与物理基础，以及生物、机理和结构方面的基础。

• The accepted article repertoire runs from letters and comprehensive articles through to reviews and perspectives, and the guidelines add comments with replies and tutorials.接收的文章类型从信件与完整论文一直排到综述与观点文章，作者指南另外还列有评论加回复与教程。

History

• The national library of medicine catalogue gives the imprint as Columbus, Ohio with the American Chemical Society and dates the title from 2021.美国国立医学图书馆目录把刊载地记为美国俄亥俄州哥伦布市，出版者为美国化学会，创刊时间记在 2021 年。

• The same record states that the journal began with volume 1, issue 1 on 15 December 2021.同一份记录写明该刊自 2021 年 12 月 15 日的第 1 卷第 1 期创刊。

• The catalogue registers a single electronic ISSN, 2694-2437, and describes the title as an open access journal from the American Chemical Society.该目录只登记了一个电子国际标准刊号 2694-2437，并把刊名释义为美国化学会旗下的开放获取期刊。

• The launch editorial appeared in that first issue and was published online on 7 September 2021.创刊社论就刊在该创刊期上，在线发表时间为 2021 年 9 月 7 日。

• Its authors invited submissions to the new open access journal and set out the founding context, the formation of cOAlition S in 2018 by a group of national research funders and the European Research Council to support the aims of Plan S.该社论作者向这家新的开放获取期刊邀稿，并交代了创刊背景，即 2018 年一批国家科研资助机构与欧洲研究理事会组成 cOAlition S 以支持 Plan S 的目标。

• A second editorial in the same first issue explained the funding mandates behind the launch of nine fully open access ACS Au journals.同一创刊期中的另一篇社论解释了美国化学会推出九种完全开放获取 Au 期刊背后的资助政策动因。^[2]

• The journal belongs to the family of ten Au titles that ACS launched in 2021.该刊属于美国化学会 2021 年推出的十种 Au 期刊。

• That portfolio grew out of the publisher's earlier open access ventures, which began with ACS Central Science in 2015 and ACS Omega in 2016.这一组合源自出版方更早的开放获取尝试，起点是 2015 年的 ACS Central Science 与 2016 年的 ACS Omega。

• The family pairs a large selective multidisciplinary chemistry journal, JACS Au, with the flagship Journal of the American Chemical Society.这一家族把大型的多学科化学期刊 JACS Au 与旗舰刊 Journal of the American Chemical Society 配成姊妹关系。

• The remaining nine titles in the family are fully open access and community focused, and this journal is one of them.家族中其余九种刊物均为完全开放获取并面向具体学术社群，本刊即在其中。

• All ten Au journals received their first full Journal Impact Factors in the 2024 Journal Citation Reports.这十种 Au 期刊在 2024 年的期刊引文报告中首次获得完整的期刊影响因子。

• The publisher's retrospective on the family marked five years of the portfolio in February 2025.出版方关于这一家族的回顾社论在 2025 年 2 月为这个出版组合的五周年作了标记。

• The journal has appeared six times a year and publishes one volume per year, with the six issues of volume 4 in 2024 dated on the even months from February to December.该刊每年出六期且每年一卷，2024 年第 4 卷的六期分别落在 2 月到 12 月之间的偶数月份。

• The volume number follows the calendar year, so volume 4 covers 2024 and volume 6 opened in 2026.卷号与年份同步，第 4 卷对应 2024 年，第 6 卷于 2026 年开卷。

• The crossref deposit record for the title gives one ISSN, 2694-2437, registered for both print and electronic, and names the American Chemical Society as publisher.Crossref 的期刊记录只给出 2694-2437 一个刊号，印刷与电子同号，出版者栏写的是美国化学会。

• The publisher keeps the journal among its fully open access titles, where all published work is free to readers from the moment it appears.出版方把该刊列在完全开放获取刊物之中，其中所有成果一发表即对读者免费开放。

Editors

• The editor in chief is (Shelley D. Minteer).主编是（Shelley D. Minteer）。

• (Squire J. Booker) is deputy editor and is at the same time an executive editor for Biochemistry.副主编是（Squire J. Booker），他同时担任 Biochemistry 的执行编辑。

• (Afsaneh Lavasanifar) is an associate editor and is also an associate editor for Molecular Pharmaceutics.副编辑之一是（Afsaneh Lavasanifar），她同时也是 Molecular Pharmaceutics 的副编辑。

• (Stuart J. Conway) is an associate editor and is also an associate editor for the Journal of Medicinal Chemistry.副编辑之一是（Stuart J. Conway），他同时也是 Journal of Medicinal Chemistry 的副编辑。

• The publisher's retrospective on the Au family records Conway as an associate editor of this title from 2021 to 2023.出版方关于 Au 家族的回顾社论把 Conway 记为本刊 2021 年至 2023 年的副编辑。^[3]

• (Matthias Gehringer) of the University of Tübingen was appointed an associate editor of the title in 2025.图宾根大学的（Matthias Gehringer）于 2025 年获任本刊副编辑。

• (Amelia Newman) is the managing editor.执行编辑是（Amelia Newman）。

• The retrospective on the family published in February 2025 was written by (Paul D. Goring), (Amelia Newman), (Christopher W. Jones) and (Shelley D. Minteer).2025 年 2 月发表的家族回顾社论由四位作者合写，作者分别是（Paul D. Goring）、（Amelia Newman）与（Christopher W. Jones），以及（Shelley D. Minteer）。

• The publisher's guidelines ask that correspondence be addressed to the editor in chief at the journal's own editorial address.出版方作者指南要求把通信寄给主编，地址使用本刊自己的编辑部信箱。

• All manuscripts are subject to critical, single anonymized peer review.所有稿件都接受严格的单盲匿名评审。

• The final decision on the suitability of a manuscript rests solely with the editor.稿件是否适合发表的最终决定完全由编辑作出。

• The journal neither confirms nor denies speculation about the identity of reviewers, and it disapproves of attempts by authors to determine it.该刊对审稿人身份的猜测既不确认也不否认，并不赞成作者试图查明审稿人身份。

• An appeal must be sent within one month of the decision, only one appeal is considered per manuscript, and the editorial team may consult further editors.申诉须在决定作出后一个月内提出，每篇稿件只受理一次申诉，编辑部还可召集其他编辑商议。

• Suggesting reviewers is optional, conflicts of interest are discouraged and institutional email addresses are preferred.推荐审稿人属自愿，官方不希望出现利益冲突，并建议提供机构邮箱地址。

• If a paper is declined the editors may suggest a manuscript transfer to another ACS journal.稿件被拒时，编辑可以建议把稿件转投美国化学会的其他期刊。

• Articles must be characterised by the editor and the referees as an advance representing the top ten per cent of papers published annually in the field, and abstracts are typically limited to 300 words.论文须由编辑与审稿人认定为该领域年度所发论文中前百分之十的进展，摘要通常限 300 词。

• Letters are capped at 2200 words including titles, footnotes and captions of about five graphics.信件的字数上限为 2200 词，题名、脚注与约五幅图注一并计入。

• Comments are permitted on recent papers and answered by a reply, but comments on papers more than five years old or in other journals are not allowed.读者可对近期论文发表评论并由回复作答，但不对五年以上的旧文或其他期刊的论文发评论。

• Authors retain copyright and may publish under CC BY-NC-ND with the option to upgrade to CC BY.作者保留著作权，可选择以 CC BY-NC-ND 发表，也可升级为 CC BY。

• The publisher's open access pricing lists 3500 US dollars for the CC BY option and 3000 US dollars for CC BY-NC-ND, with the article publishing charge fully waived for corresponding authors in World Bank Group A countries and halved for Group B countries, and ACS Premium members receive 250 US dollars off.出版方的开放获取定价表列出 CC BY 选项 3500 美元、CC BY-NC-ND 选项 3000 美元，通讯作者身处世界银行 A 组国家时文章出版费全免，B 组国家减半，会员另减 250 美元。

• Authors at institutions covered by an ACS read and publish agreement can have the charge met by that agreement.所在机构与美国化学会签有阅读与出版协议的作者，费用可由该协议承担。

• Articles are deposited automatically in PubMed Central and Europe PMC after the issue and the licence are complete.文章在期号与许可确定后会自动存入 PubMed Central 与 Europe PMC。

• The journal invites cover images for its front cover or for a paid supplementary cover, and the printed size is 8.19 by 10 inches at 300 pixels per inch.该刊欢迎为封面或付费补充封面投稿图片，印刷尺寸为宽 8.19 英寸高 10 英寸，分辨率 300 像素每英寸。

• Submissions are screened for plagiarism with the iThenticate service, and tools based on artificial intelligence cannot be listed as authors, so any use of them has to be disclosed in the acknowledgements.投稿以 iThenticate 服务查重，基于人工智能的工具不能署名作者，但须在致谢中披露。